Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...

Shionogi & Co. has been awarded a $375 ... The company is dedicated to advancing public health by developing products and services that address pandemics, with a commitment to equitable access ...

Iwasaki attributed the decision to shifts in business strategies and emphasized that Shionogi will focus on ... billion for COVID-19 and influenza products combined. Analysts expressed skepticism ...

Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hyperactivity disorder (ADHD ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with ... with the World Health Organization (WHO) warning that antimicrobial resistance (AMR ...

At close: February 12 at 2:58:58 PM EST ...

Investors might want to bet on Shionogi & Co., Ltd. Unsponsored ADR (SGIOY), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / February 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based ...